Data demonstrates the performance of OVASight in a low prevalence population- 89% Specificity, 91% Sensitivity and a Negative Predictive Value of 99.6% for the management of suspected Benign Pelvic ...
Artificial intelligence (AI) models can generate scientific abstracts that are difficult to distinguish from the work of human authors. The use of AI in scientific writing and performance of AI ...
Biosimilars offer increased patient choice and potential cost-savings, compared with originator biologics. We studied 3 years of prescribed biologics among US physician practices to determine the ...
Tips to Reduce Treatment Downtime in Lung Cancer Dr Mark Kris discusses waiting in the oncology setting, focusing on the importance of communication with colleagues and with patients. Medscape ...
CINCINNATI, May 19, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) announced that Aadi Bioscience (“Aadi”), a privately-held biopharmaceutical company focusing on ...
Data from 20 abstracts demonstrate value of company’s blood tests across the continuum of cancer care, including: screening, therapy selection, residual and recurrent disease detection, and ...
Latest data from study TK216-01 remain encouraging, are consistent with previous results, and are updated over data contained in ASCO Abstract #11500 released today Two patients who achieved a ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Today, Sarah Cannon announced it will present its latest cancer research insights at the American Society of Clinical Oncology’s (ASCO®) Annual Meeting being held ...
Melanoma Updates From ASCO 2023: PD-1 and LAG-3 Jeffrey S. Weber, MD, PhD, discusses updates related to melanoma practice and care from ASCO 2023. Experts And Viewpoints, October 24, 2023 Society for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback